BC Innovations | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
BC Week In Review | Jan 27, 2017
Company News

UCSD, U of Manitoba, St. Boniface Hospital Albrechtsen Research Center, WinSanTor deal

The organizations granted WinSanTor an exclusive license to develop and commercialize small molecule antagonists of muscarinic receptor to treat peripheral neuropathy. The lead compound, WST-057 , is in Phase I trials for the indication, with Phase...
Items per page:
1 - 2 of 2
BC Innovations | Feb 16, 2017
Translation in Brief

WinSanTor, with feeling

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started...
BC Week In Review | Jan 27, 2017
Company News

UCSD, U of Manitoba, St. Boniface Hospital Albrechtsen Research Center, WinSanTor deal

The organizations granted WinSanTor an exclusive license to develop and commercialize small molecule antagonists of muscarinic receptor to treat peripheral neuropathy. The lead compound, WST-057 , is in Phase I trials for the indication, with Phase...
Items per page:
1 - 2 of 2